Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035
Type 1
Diabetes Mellitus (T1D) Market Outlook
Thelansis’s “Type 1 Diabetes
Mellitus (T1D) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2025 To 2035” covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Type 1
Diabetes Mellitus (T1D) treatment modalities options for eight
major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Type 1
Diabetes Mellitus (T1D) Overview
Type 1
diabetes mellitus (T1D) is a chronic autoimmune disorder driven by
immune-mediated pancreatic beta-cell destruction, resulting in absolute insulin
deficiency. Genetic susceptibility — particularly HLA-DR3/DR4 alleles —
combined with environmental triggers initiates autoreactive T-cell
infiltration; GAD65, IA-2, and ZnT8 autoantibodies serve as diagnostic and
predictive biomarkers. Patients typically present with polyuria, polydipsia,
weight loss, and fatigue, with many diagnosed during diabetic ketoacidosis.
Diagnosis combines plasma glucose, HbA1c, and autoantibody profiling, with
C-peptide reflecting residual beta-cell function. Insulin therapy — via
multiple daily injections or closed-loop automated delivery systems integrated
with continuous glucose monitoring — remains the therapeutic cornerstone,
targeting individualised HbA1c goals while minimising hypoglycaemia.
Teplizumab, an anti-CD3 monoclonal antibody, can delay onset in high-risk
individuals, marking a significant therapeutic advance. Monitoring encompasses
regular screening for retinopathy, nephropathy, and neuropathy alongside
cardiovascular risk optimisation. Prognosis has improved considerably with
modern technology; however, psychosocial burden remains substantial, making
psychological support, patient education, and shared decision-making essential
to empowering long-term, quality-focused management.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and
China)
Insights driven by robust research, including:
- In-depth
interviews with leading KOLs and payers
- Physician
surveys
- RWE analysis
for claims and EHR datasets
- Secondary
research (e.g., peer-reviewed journal articles, third-party research
databases)
Deliverables format and updates*:
- Detailed Report
(PDF)
- Market Forecast
Model (MS Excel-based automated dashboard)
- Epidemiology
(MS Excel; interactive tool)
- Executive
Insights (PowerPoint presentation)
- Others: regular
updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent
updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market
forecast (2025–2035)
- Bottom-up
patient-based market forecasts validated through the top-down sales
methodology
- Covers
clinically and commercially-relevant patient populations/ line of
therapies
- Annualized
drug-level sales and patient share projections
- Utilizes our
proprietary Epilansis and Analog tool (e.g., drug uptake and erosion)
datasets and conjoint analysis approach
- Detailed
methodology/sources & assumptions
- Graphical and
tabular outputs
- Users can
customize the model based on requirements
Key business questions answered:
- How can drug
development and lifecycle management strategies be optimized across G8
markets (US, EU5, Japan, and China)?
- How large is
the patient population in terms of incidence, prevalence, segments, and
those receiving drug treatments?
- What is the
10-year market outlook for sales and patient share?
- Which events
will have the greatest impact on the market’s trajectory?
- What insights
do interviewed experts provide on current and emerging treatments?
- Which pipeline
products show the most promise, and what is their potential for launch and
future positioning?
- What are the
key unmet needs and KOL expectations for target profiles?
- What key
regulatory and payer requirements must be met to secure drug approval and
favorable market access?
- and more…
Comments
Post a Comment